PARP1 and prostate carcinoma: With a deeper understanding of the molecular mechanisms of the disease and the discovery of different subtypes of prostate cancer, poly (ADP‐ribose) polymerase (PARP) inhibitors, which have emerged in recent years, offer new hope.